Inhibitex

Pomerantz is investigating claims on behalf of investors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (NASDAQ:INHX) concerning the proposed acquisition of Inhibitex by Bristol-Myers Squibb Company (“Bristol-Myers”) in a cash transaction valued at approximately $2.5 billion.

The investigation concerns whether the Inhibitex directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Through the acquisition, Bristol-Myers stands to gain a very lucrative position in the Hepatitis C drug industry at a time when it is losing patent protection on three of its four top selling drugs. Under the terms of the agreement shareholders would receive $26.00 per share - at least one analyst has set a target price of $34.00 per share.

Inhibitex shareholders seeking more information about this acquisition are advised to contact Gustavo Bruckner, Esq. at gfbruckner [at] pomlaw [dot] com or 212-661-1100 or toll free at 888-476-6529, ext. 302. Shareholders may also contact Rachelle R. Boyle at rrboyle [at] pomlaw [dot] com or 212-661-1100 or 888-476-6529, ext. 237.